A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms

Conditions: Myeloproliferative Disorders; Essential Thrombocythemia; Neoplasms; Myelofibrosis Interventions: Drug: JNJ-88549968 Sponsors: Janssen Research& Development, LLC Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials